Vigabatrin for Treatment of Cocaine Dependence

Cocaine Dependence Clinical Trial

Official title:

Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00611130
• Other study ID #: CPP-01004
• Status: Completed
• Phase: Phase 2
• First received: January 28, 2008
• Last updated: March 14, 2016
• Start date: January 2008
• Est. completion date: October 2012

Study information

• Verified date: March 2016
• Source: Catalyst Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.

Description:

Cocaine addiction, a serious public health concern associated with significant medical, social, and economic consequences, is difficult to treat using traditional psychosocial and behavioral therapies. Despite testing of a number of different agents for cocaine dependency, there remains no proven pharmacologic treatment for cocaine addiction.

The addictive properties of cocaine have been associated with its actions on mesotelencephalic dopamine reward pathways in the central nervous system (CNS). Cocaine administration increases the levels of dopamine, a neurotransmitter associated with sensations of pleasure and reward. Therefore, blocking cocaine-induced increases in dopamine levels represents a valid pharmaceutical approach to the treatment of cocaine addiction.

Another neurotransmitter, gamma-aminobutyric acid (GABA), suppresses striatal dopamine release, and attenuates cocaine-induced increases in extracellular and synaptic dopamine levels in the striatum and nucleus accumbens in animal models of drug dependence. Significant elevation of brain GABA levels may reduce cocaine-stimulated dopamine release and dampen the sensations of pleasure and reward. Thus, drugs that potentiate or enhance GABA-ergic transmission are candidates for the treatment of cocaine addiction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 186
• Est. completion date: October 2012
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Able to understand the study and provide written informed consent.

• Male or female at least 18 years of age.

• Meets DSM-IV (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) criteria for cocaine dependence as primary diagnosis, as determined by the Substance Abuse module of SCID (Structured Clinical Interview for DSM-IV).

• Provide at least one urine sample that is positive for cocaine according to a rapid screening test.

• Seeking treatment for cocaine dependence.

• Have normal visual fields.

• Be in generally good health based on history, physical examination, electrocardiogram and laboratory findings.

• If female of childbearing potential, use acceptable contraceptive methods. (oral contraceptives (the pill), IUDs, contraceptive implants under the skin, contraceptive rings or patches or injections, diaphragms with spermicide, and condoms with spermicide). Surgical sterilization by tubal ligation or hysterectomy is acceptable

Exclusion Criteria:

• Has current dependence, as determined by the SCID, on any psychoactive substance other than cocaine, alcohol, nicotine, or marijuana or physiologic dependence on alcohol requiring medical detoxification.

• Has any serious medical or psychiatric illness and/or clinically significant abnormal laboratory value, which in the judgment of the Principal Investigator or his/her designee would make study participation unsafe, or would make treatment compliance difficult or put the study staff at undue risk.

• Be under court mandate to obtain treatment.

• Be enrolled in an opiate substitution treatment program within 2 months of randomization.

• Has ever taken vigabatrin in the past.

• Is pregnant or lactating.

• Has clinically significant ophthalmologic disease, which would preclude safety monitoring or is undergoing treatment for ocular disease.

• Has received a drug with known major organ toxicity, including retinotoxicity within 30 days of randomization.

• Is currently participating in, or has been enrolled in another clinical trial within the last 30 days.

• Be anyone who, in the judgment of the investigator, would not be expected to attend regular study visits or to complete the study protocol, due to imminent relocation from the clinic area, legal difficulties, work-related problems, transportation, etc.

Related Conditions & MeSH terms

• Cocaine Dependence
• Cocaine-Related Disorders

Intervention

Drug:
• vigabatrin
Tablets twice a day for 9 weeks
• placebo
tablets twice daily for 9 weeks

Locations

Country	Name	City	State
United States	Johns Hopkins Bayview Medical Center Center for Chemical Dependence	Baltimore	Maryland
United States	Boston University School of Medicine	Boston	Massachusetts
United States	Cincinnati Addiction Research Center (CinARC)	Cincinnati	Ohio
United States	Dayton Veterans Affairs Medical Center	Dayton	Ohio
United States	Operation PAR	Largo	Florida
United States	Addiction Treatment Clinic	Little Rock	Arkansas
United States	New York University Mental Health and Addictive Disorders Research Program	New York	New York
United States	Segal Institute for Clinical Research	North Miami	Florida
United States	University of Texas Health Science Center at San Antonio	San Antonio	Texas
United States	St. Luke's Hospital Addiction Pharmacology Research Laboratory	San Francisco	California
United States	Friends Research Institute	Torrance	California

Sponsors (1)

Lead Sponsor	Collaborator
Catalyst Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment.	Number of subjects in the CPP-109 Vigabatrin Group vs. Number in Placebo Group abstinent from using cocaine during Weeks 11 and 12 of the Treatment Phase.	Week 13